Lee Chan Henry sold $418K of ONC
Lee Chan Henry (SVP, General Counsel) sold 1,115 shares of BeOne Medicines Ltd. (ONC) at $375.00 ($0.42M total) on 2026-09-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The insider's complete exit may be interpreted by investors as a lack of confidence, potentially prompting short-term sell pressure.
Market read
A primary SEC Form 4 filing revealing a complete insider exit, modest in dollar terms but notable for its completeness.
What to watch
Potential upcoming clinical data or regulatory events not reflected in the filing.
Background
BeOne Medicines Ltd. (ONC) is a clinical-stage biotech focused on oncology therapies.
Ticker impact
Form 4 disclosed SVP Lee Chan Henry sold 1,115 shares for $418,125, reducing his holdings to zero.
likely pressure as the market prices in the insider sell.
The sale is sizable relative to the insider's position and was executed via a 10b5-1 plan, suggesting a planned exit rather than a reaction to new information.
Market effects
Minimal impact on biotech sector; typical insider sales are routine.
None
None
Counterpoint
The sale could be unrelated to company fundamentals and merely a portfolio rebalancing.
Key entities
- OfficerLee Chan Henry
SVP, General Counsel of BeOne Medicines Ltd.
